Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Cybersecurity ETF (HACK) vs 10X Genomics Inc (TXG) Price & Performance

Amplify Cybersecurity ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Amplify Cybersecurity ETF vs 10X Genomics Inc — how do they compare? Amplify Cybersecurity ETF trades at $118.94, while 10X Genomics Inc trades at $59.82 (market cap $7.64B). Which is the better fit depends on your goals.

HACKTXG
Sector
Sector/ThematicHealth
52-Week High
$119.19$58.57
52-Week Low
$70.69$11.34
Market Cap
$7.64B
Enterprise Value
$7.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Cybersecurity ETF

HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.

The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Cybersecurity ETF

HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.

Read more on HACK

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG